M.D.C. Holdings, Inc. (NYSE:MDC) Declares $0.30 Quarterly Dividend

M.D.C. Holdings, Inc. (NYSE:MDC) announced a quarterly dividend on Monday, October 28th, Zacks reports. Shareholders of record on Wednesday, November 13th will be given a dividend of 0.30 per share by the construction company on Wednesday, November 27th. This represents a $1.20 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date of this dividend is Tuesday, November 12th.

M.D.C. stock opened at $37.55 on Friday. M.D.C. has a one year low of $25.77 and a one year high of $46.84. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.83 and a current ratio of 9.08. The business has a fifty day moving average of $42.86 and a two-hundred day moving average of $36.86. The company has a market cap of $2.35 billion, a P/E ratio of 10.23, a price-to-earnings-growth ratio of 1.04 and a beta of 1.04.

M.D.C. (NYSE:MDC) last released its earnings results on Wednesday, October 30th. The construction company reported $0.79 EPS for the quarter, missing analysts’ consensus estimates of $0.87 by ($0.08). M.D.C. had a net margin of 6.58% and a return on equity of 12.73%. The business had revenue of $750.27 million during the quarter, compared to analyst estimates of $767.23 million. During the same period last year, the business posted $0.86 EPS. M.D.C.’s revenue was down 2.1% compared to the same quarter last year. Sell-side analysts predict that M.D.C. will post 3.54 EPS for the current year.

A number of research firms have commented on MDC. Cfra raised M.D.C. from a “hold” rating to a “buy” rating in a report on Thursday, October 31st. Zelman & Associates downgraded M.D.C. from a “buy” rating to a “hold” rating in a research note on Thursday, October 31st. Wedbush lifted their price target on M.D.C. from $35.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday, September 13th. Raymond James raised M.D.C. from an “outperform” rating to a “strong-buy” rating and lifted their price target for the stock from $42.00 to $49.00 in a research note on Friday, September 13th. Finally, ValuEngine downgraded M.D.C. from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, three have given a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $44.00.

In other news, Director Raymond T. Baker sold 41,250 shares of M.D.C. stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $42.69, for a total transaction of $1,760,962.50. Following the completion of the transaction, the director now owns 45,462 shares of the company’s stock, valued at approximately $1,940,772.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director David E. Blackford sold 4,000 shares of M.D.C. stock in a transaction on Friday, September 13th. The stock was sold at an average price of $42.40, for a total value of $169,600.00. Following the transaction, the director now directly owns 14,266 shares of the company’s stock, valued at approximately $604,878.40. The disclosure for this sale can be found here. Insiders have sold a total of 98,832 shares of company stock valued at $4,248,023 in the last ninety days. Corporate insiders own 26.30% of the company’s stock.

M.D.C. Company Profile

M.DC Holdings, Inc, through its subsidiaries, engages in the homebuilding and financial service businesses. Its homebuilding operations include purchasing finished lots or developing lots for the construction and sale primarily of single-family detached homes to first-time and first-time move-up homebuyers under the Richmond American Homes name.

See Also: 52-week highs

Dividend History for M.D.C. (NYSE:MDC)

Receive News & Ratings for M.D.C. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for M.D.C. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply